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Abstract: BACKGROUND Therapy guided by N-terminal-pro-B-type natriuretic peptide (NT-proBNP)
levels may improve outcomes in patients with chronic heart failure (HF), especially in younger patients
with reduced left ventricular ejection fraction. It remains unclear whether treatment effects persist after
discontinuation of the NT-proBNP-guided treatment strategy. METHODS AND RESULTS Trial of
Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure randomized
499 patients with HF aged￿60 years with left ventricular ejection fraction￿45% to intensified, NT-proBNP-
guided versus standard, symptom-guided therapy into prespecified age groups (60-74 and ￿75 years)
during 18 months. A total of 329 patients (92%) alive at 18 months agreed to long-term follow-up.
HF medication was intensified to a larger extent in the NT-proBNP-guided group. During long-term,
NT-proBNP-guided therapy did not improve hospital-free (primary end point: hazard ratio, 0.87; 95%
confidence interval, 0.71-1.06; P=0.16) or overall survival (hazard ratio, 0.85; 95% confidence interval,
0.64-1.13; P=0.25) but did improve HF hospitalization-free survival (hazard ratio, 0.70; 95% confidence
interval, 0.55-0.90; P=0.005). Patients aged 60 to 74 years had benefit from NT-proBNP-guided therapy
on the primary end point and HF hospitalization-free survival, whereas patients aged￿75 years did not
(P<0.10 for interaction). In landmark analysis, there was no regression to the mean after cessation
of the NT-proBNP-guided strategy. More intensified HF medication at month 12 was associated with
better long-term HF hospitalization-free and overall survival. CONCLUSIONS Intensified, NT-proBNP-
guided therapy did not improve the primary end point compared with symptom-guided therapy but
did improve HF hospitalization-free survival. Within the subgroup of patients aged 60 to 74 years,
it improved clinical outcome including the primary end point. These effects did not disappear after
cessation of the NT-proBNP-guided strategy on the long-term. This is possibly attributable to a more
intensified HF medical therapy in the NT-proBNP-guided group. CLINICAL TRIAL REGISTRATION
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Heart failure (HF) therapy guided by natriuretic pep-tides, that is, N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) or B-type natriuretic peptide (BNP), has been 
proposed to improve outcomes in patients with chronic HF 
compared with usual clinical care, especially in patients <75 
years,1–4 although individual study results were not consis-
tent.5–15 A more aggressive uptitration of HF medical therapy 
is suggested as one of the main factors responsible for the 
positive effect of a (NT-pro)BNP-guided management in that 
higher target doses of guideline-recommended HF therapy are 
achieved.16 Indeed, higher doses of renin–angiotensin system 
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Background—Therapy guided by N-terminal-pro-B-type natriuretic peptide (NT-proBNP) levels may improve outcomes 
in patients with chronic heart failure (HF), especially in younger patients with reduced left ventricular ejection fraction. 
It remains unclear whether treatment effects persist after discontinuation of the NT-proBNP–guided treatment strategy.
Methods and Results—Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure 
randomized 499 patients with HF aged ≥60 years with left ventricular ejection fraction ≤45% to intensified,  NT-proBNP–
guided versus standard, symptom-guided therapy into prespecified age groups (60–74 and ≥75 years) during 18 months. 
A total of 329 patients (92%) alive at 18 months agreed to long-term follow-up. HF medication was intensified to a larger 
extent in the NT-proBNP–guided group. During long-term, NT-proBNP–guided therapy did not improve  hospital-free 
(primary end point: hazard ratio, 0.87; 95% confidence interval, 0.71–1.06; P=0.16) or overall survival (hazard ratio, 0.85; 
95% confidence interval, 0.64–1.13; P=0.25) but did improve HF hospitalization-free survival (hazard ratio, 0.70; 95% 
confidence interval, 0.55–0.90; P=0.005). Patients aged 60 to 74 years had benefit from NT-proBNP–guided therapy on the 
primary end point and HF hospitalization-free survival, whereas patients aged ≥75 years did not (P<0.10 for interaction). In 
landmark analysis, there was no regression to the mean after cessation of the NT-proBNP–guided strategy. More intensified 
HF medication at month 12 was associated with better long-term HF hospitalization-free and overall survival.
Conclusions—Intensified, NT-proBNP–guided therapy did not improve the primary end point compared with  symptom-
guided therapy but did improve HF hospitalization-free survival. Within the subgroup of patients aged 60 to 74 years, 
it improved clinical outcome including the primary end point. These effects did not disappear after cessation of the  NT-
proBNP–guided strategy on the long-term. This is possibly attributable to a more intensified HF medical therapy in the 
NT-proBNP–guided group.
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(RAS) blockade by either angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers and β-blockers 
and higher usage of mineralocorticoid antagonists (MRAs) 
were reached in most (NT-pro)BNP-guided therapy stud-
ies.5,7,10,12,15,17 This might also improve outcomes on the long 
term, but (NT-pro)BNP-guided studies performed to date did 
not extend follow-up beyond the intervention period with one 
exception—NT-proBNP–Assisted Treatment To Lessen Serial 
Cardiac Readmissions and Death (BATTLESCARRED) 
included a 2-year intervention period and an additional year of 
follow-up.8 Therefore, it remains unclear whether the treatment 
effects persist long term after discontinuation of the  (NT-pro)
BNP-guided treatment strategy. The Trial of Intensified versus 
standard Medical therapy in Elderly patients with Congestive 
Heart Failure (TIME-CHF) is to date largest trial in this 
regard, showing improved outcomes by NT-proBNP–guided 
therapy in patients aged 60 to 75 years, but not in those aged 
≥75 years.7 To estimate the long-term effects of NT-proBNP–
guided therapy and to investigate whether the early benefit 
observed in TIME-CHF sustains during the long term, mainly 
in patients aged 60 to 74 years, we hereby report the 5-year 
results of NT-proBNP–guided versus symptom-guided HF 
therapy in TIME-CHF.
Methods
Study Design and Subjects
The TIME-CHF was a multicenter, randomized trial conducted in 
15 centers in Switzerland and Germany. The trial design and meth-
ods have been published in detail previously.18 In short, 499 pa-
tients with symptomatic HF aged ≥60 years with a left ventricular 
ejection fraction of ≤45% were randomized to an intensified, NT-
proBNP–guided versus a standard, symptom-guided therapy. Patients 
were a priori stratified into 2 age groups (ie, 60–74 and ≥75 years). 
 Guideline- recommended medication was intensified according to 
predefined escalation rules with the goal to reduce symptoms to New 
York Heart Association class II or less in the symptom-guided group 
and to additionally reduce NT-proBNP levels to <2× the upper limit 
of normal (ie, 400 ng/L in those 60–74 years and 800 ng/L in those 
≥75 years) in the NT-proBNP–guided group. Study visits took place 
at 1, 3, 6, 12, and 18 months. Up to month 12, therapy was adjust-
ed in collaboration with the treating general practitioners with the 
goal to uptitrate therapy as far as possible within 6 months. After the 
initial 18-month study period, 329 of 358 patients (92%) alive and 
participating in the study agreed to long-term follow-up (Figure I in 
the Data Supplement), which was conducted by telephone contact 
and chart review and was continued up to >5 years. End points were 
survival free of all-cause hospitalization, survival free of HF hospital-
izations, and overall survival (excluding cancer-related death by pro-
tocol). Patients who were lost to follow-up (n=2) or withdrew from 
the trial declining further contact (n=18) were censored at the time of 
last contact. Patients who declined telephone follow-up beyond the 
trial period (n=29) were censored at month 18 (Figure I in the Data 
Supplement). The study was approved by the ethics committees of 
each center and each patient gave written informed consent before 
entering the study.
Statistical Analysis
Results are presented as frequencies (%), mean (SD), or median (in-
terquartile range), as appropriate. RAS blockade and β-blocker doses 
are presented as percentage of target dose as recommended by the 
European Society of Cardiology HF guideline (Table I in the online-
only Data Supplement).  Between-group comparisons were performed 
using the t test, Mann–Whitney test, or Pearson χ2. Survival and 
event-free survival was analyzed by the Kaplan–Meier method using 
the log-rank test to compare groups and by Cox proportional haz-
ard regression models. Besides age groups, which were predefined 
by protocol, other subgroup analyses were exploratory. Interactions 
of the main effect were tested using Cox proportional hazard regres-
sion models correcting for the other investigated subgroup variables, 
that is, age, sex, New York Heart Association class, left ventricular 
ejection fraction, ischemic cause of HF, body mass index, comorbidi-
ties, renal failure, and baseline NT-proBNP-level, to control for con-
founding. Finally, we performed a landmark analysis to determine a 
patient’s survival by response, using the 12-month uptitration phase 
of the study as the landmark time point. Note that in this landmark 
analysis, patients who die before 12 months were excluded from the 
analysis. Landmark analysis was performed for treatment groups 
and as a secondary analysis we divided patients by achieved dose of 
guideline-recommended HF treatment at month 12. The Cox propor-
tional hazards assumption was tested by (1) log-minus-log survival 
plots, (2) comparing 2 discrete time intervals, and (3) adding a time-
dependent interaction term. The models for treatment groups did not 
show a departure from proportionality. The models for intensification 
of medication, a secondary analysis, did not fulfill the assumption 
and therefore, Kaplan–Meier plots are presented. A 2-sided P value 
of 0.05 was considered to be statistically significant; for interaction 
tests a 2-sided P value of 0.10 was considered statistically significant. 
All calculations were performed with the use of the SPSS statistical 
package version 18.0 (SPSS Inc, Chicago, IL).
Results
Baseline Characteristics
Patient characteristics at baseline have been published in 
detail previously,7 a summary is shown in Table 1. Base-
line characteristics were similar between treatment groups, 
reflecting randomized allocation. Patients were overall 
elderly, predominantly men, had mainly ischemic HF with 
Table 1. Baseline Characteristics
Characteristics
Symptom Guided  
(n=248)
NT-ProBNP Guided 
(n=251) P Value
Age, y 77±8 76±7 0.16
Sex (women) 92 (37%) 80 (32%) 0.22
BMI, kg/m2 25.3±4.3 24.4±4.0 0.75
NYHA class 0.61
  II 63 (25%) 65 (26%)
  III 149 (60%) 157 (63%)
  IV 36 (15%) 29 (12%)
Ischemic cause HF 149 (60%) 138 (55%) 0.28
Systolic BP, mm Hg 119±19 118±18 0.97
LVEF, % 29.7±7.9 29.8±7.7 0.87
NT-proBNP, pg/mL 4657 [2455–7520] 3998 [2075–7220] 0.12
Creatinine, mg/dL 1.33±0.42 1.32±0.45 0.69
Comorbidities ≥2 182 (73%) 181 (72%) 0.76
Renal failure 135 (54%) 140 (56%) 0.79
Atrial fibrillation 78 (32%) 82 (33%) 0.94
Diabetes mellitus 95 (38%) 77 (31%) 0.08
Data are presented as mean (SD), median [IQR], or frequency (%). BMI indicates 
body mass index; BP, blood pressure; HF, heart failure; LVEF, left ventricular 
ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and 
NYHA, New York Heart Association. Adapted from Pfisterer et al7 with permission 
of the publisher (American Medical Association, 2009). Authorization for this 
adaptation has been obtained both from the owner of the copyright in the original 
work and from the owner of copyright in the translation or adaptation.
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severe symptoms as reflected by high New York Heart Asso-
ciation classification and high NT-proBNP levels. The pres-
ence of comorbidities was high. Background HF therapy 
at baseline was similar between groups, with a high use of 
RAS blockade and β-blockers although at suboptimal doses 
according to the HF guidelines.16 Patients aged ≥75 years 
had more comorbidities, higher New York Heart Association 
classification, higher NT-proBNP, and lower left ventricular 
ejection fraction compared with patients aged 60 to 74 years. 
Also, patients in the older age group received less optimal HF 
medical therapy than the younger age group (Table II in the 
Data Supplement).
Intensification of Medical HF Therapy
At the end of the 12-month uptitration period, guideline- 
recommended medical HF treatment was installed and upti-
trated to a greater extent in the NT-proBNP–guided group 
compared with the symptom-guided group (Table 2), with 
regard to RAS blockade, β-blockers, and MRAs. There was 
a nonsignificant trend toward less use of diuretics in the NT-
proBNP–guided group compared with the  symptom-guided 
group. There were no significant changes in therapy beyond 
the 12-month uptitration period toward the 18-month final 
visit (data not shown).
Although the more elderly had lower mean and achieved 
doses or RAS and β-blockade at 12 months compared with 
the relatively younger patients, NT-proBNP–guided therapy 
had similar positive effects on RAS and β-blockade uptitra-
tion in the younger versus the older age group. MRAs were 
more significantly intensified by NT-proBNP–guided therapy 
in the older age group, whereas NT-proBNP–guided therapy 
lowered diuretic usage only in the younger patients (Table III 
in the Data Supplement).
Long-Term Outcome
During follow-up, 199 patients died (39.9%). Of those, 6 
died of cancer and were censored at the time of death. Cause 
of death was predominantly cardiovascular.19 A total of 254 
patients (50.9%) experienced the disease-specific end point of 
HF hospitalization or death and 379 patients (76.0%) experi-
enced the end point of all-cause hospitalization or death with 
a median follow-up of 26 months (interquartile range, 16–41).
Intensified, NT-ProBNP–Guided Therapy Versus  Symptom-
Guided Therapy
Hospital-free survival (Figure 1A, left) and overall sur-
vival (Figure 1C, left) were not significantly reduced by 
NT-proBNP–guided therapy, but there was a significant 
demonstrable benefit of NT-proBNP–guided therapy on the 
disease-specific end point of HF hospitalization-free survival 
(Figure 1B, left). Performing several sensitivity analyses, that 
is, (1) excluding patients who discontinued the study regime 
before 12 months (n=46), (2) treating those who were lost or 
withdrawn without further contact (n=20) as having died, and 
(3) additionally treating those who refused follow-up beyond 
18 months (n=29) as having died, did not alter the results (data 
not shown).
Influence of Patient Characteristics on Treatment Effect
The long-term effects of NT-proBNP–guided therapy were 
more favorable in patients aged 60 to 74 years compared 
with patients aged ≥75 years (P for interaction 0.05 for 
hospital-free survival, P=0.06 for HF hospital-free survival, 
and P=0.09 for overall survival; Figure 2) with a significant 
positive effect of NT-proBNP–guided therapy on the primary 
end point (Figure 1A, middle) and HF hospitalization-free 
survival (Figure 1B, middle) in the predefined younger age 
group. Further subgroup analyses suggested interactions with 
comorbidity burden, body mass index, baseline NT-proBNP 
concentration, kidney disease, and sex (Figure 2).
Landmark Analysis
Baseline characteristics and 12-month clinical characteristics 
were similar in both treatment groups for the patients included 
in the landmark analysis (Table IV in the Data Supplement), 
besides a higher prevalence of diabetes mellitus in the symp-
tom-guided group. Landmark analysis showed that there was 
Table 2. HF Medical Therapy in the 12-Month Uptitration 
Period by Treatment Group
Symptom  
Guided  
(n=175)
NT-ProBNP  
Guided  
(n=195) P Value
RAS blockade (percentage of target dose)*
  Absolute uptitration 12.5 [0–50] 50 [0–75] <0.001
  At 12 mo, n (%) 166 (95%) 189 (97%) 0.31
  Achieved dose 62.5 [50–100] 100 [50–100] 0.001
  Average daily dose 81 [49–100] 87 [55–100] 0.01
β-Blockade (percentage of target dose)*
  Absolute uptitration 12.5 [0–25] 25 [0–50] <0.001
  At 12 mo, n (%) 164 (94%) 176 (90%) 0.22
  Achieved dose 25 [19–100] 37.5 [25–75] 0.27
  Average daily dose 32 [16–52] 37 [21–53] 0.28
MRA (spironolactone equivalent)†
  Absolute uptitration 0 [0–0] 0 [0–25] 0.013
  Started during 12 mo, n (%) 23 (15%) 41 (23%) 0.03
  At 12 mo, n (%) 63 (36%) 98 (50%) 0.009
  Achieved dose 0 [0–25] 6.25 [0–25] 0.003
  Average daily dose 2 [0–20] 12 [0–25] 0.04
Loop diuretics (furosemide equivalent)‡
  Absolute uptitration 20 [0–80] 10 [0–80] 0.60
  At 12 mo, n (%) 163 (93%) 170 (87%) 0.06
  Achieved dose 40 [40–80] 40 [20–80] 0.40
  Average daily dose 56 [32–86] 48 [30–93] 0.15
Data are presented as median [IQR] or frequency (%). Max uptitration: 
maximum dose increase from baseline; achieved dose: the actual dose at the end 
of the uptitration period; average daily dose: the average daily dose during the 
uptitration period; calculated per patient separately using the daily medication 
data to present the actual dose that the patient received in this period. HF 
indicates heart failure; MRA, mineralocorticoid receptor antagonist; NT-proBNP, 
N-terminal pro-B-type natriuretic peptide; and RAS, renin–angiotensin system.
*Percentage of target dose as recommended by the European Society of 
Cardiology HF guideline,16 see Table I in the Data Supplement.
†Dose represents spironolactone dose in milligram.
‡Dose represents furosemide equivalent in milligram (10 mg torasemide 
equals 40 mg furosemide).
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no significant effect of NT-proBNP–guided treatment on 
hospitalization-free survival (hazard ratio [HR] 0.81; 95% 
confidence interval [CI], 0.63–1.04; P=0.10), HF hospital-
ization-free survival (HR, 0.76; 95% CI, 0.55–1.05; P=0.10), 
or overall survival (HR, 1.001; 95% CI, 0.68–1.48; P=0.99) 
beyond the initial 12-month uptitration period. Nonetheless, 
the effect observed during the first 12 months was contin-
ued (ie, not reversed) after NT-proBNP–guided therapy was 
ceased (Figure 1).
In the prespecified younger age group, there was a posi-
tive effect of NT-proBNP–guided therapy on the primary 
end point hospitalization-free survival (HR, 0.67; 95 CI, 
0.45–0.99; P=0.046) and a nonsignificant effect on HF 
hospitalization-free survival (HR, 0.58; 95% CI, 0.33–1.02; 
P=0.057) but no effect on overall survival (HR, 0.77; 95% 
CI, 0.39–1.52; P=0.46) in the landmark analysis. There was 
no landmark effect of NT-proBNP–guided treatment on out-
come in the older age group (P≥0.50 values for all end points). 
Interactions between age groups and treatment allocation 
were not significant (hospitalization-free survival, P=0.17; 
HF hospitalization-free survival, P=0.19; and overall survival, 
P=0.35).
Intensification of Medical HF Therapy and Outcome
Patients in the landmark analysis were divided according to 
achieved medical therapy at month 12, reflecting response to 
Figure 1. Kaplan–Meier curves for long-term outcome divided by treatment groups. A, Heart failure (HF) hospitalization-free survival; 
(B) hospital-free survival; and (C) overall survival. Solid line, N-terminal-pro-B-type natriuretic peptide (NT-proBNP) guided; dashed line, 
symptom-guided. The vertical line indicates the landmark point and the end of the 12-month uptitration period. HR indicates hazard ratio.
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the guided strategy. Patients with levels of RAS blockade and 
β-blockers at 12 months ≥50% of target dose had better HF 
hospitalization-free survival and overall survival compared 
with those with lower levels of RAS blockade and β-blockers, 
but there was no effect on hospitalization-free survival (Fig-
ure 3A). Results were similar when additionally considering 
the installation of a MRA (Figure 3B). Higher levels of medi-
cal HF therapy positively influenced outcomes in the younger 
age group but not in the older age group (Table V in the  Data 
Supplement).
Discussion
The principal findings of the study are that intensified, 
 NT-proBNP–guided therapy does not improve the primary 
end point of the study, whereas the positive effect of inten-
sified, NT-proBNP–guided therapy on the disease-specific 
outcome observed during the intervention period persists 
thereafter, that is, when NT-proBNP levels are no longer 
measured after uptitration, resulting in an improvement of 
long-term survival free of HF hospitalization as compared 
with symptom-guided therapy in patients with HF aged ≥60 
years. The persisting long-term effect was only seen in the 
relatively younger patients aged 60 to 74 years, confirming 
the early effect they experienced, but not in the more elderly. 
Finally, the positive and long-term effect of  NT-proBNP 
guidance seems to be related to a more intensified use of 
HF medication.
During the 18-month main trial period of TIME-CHF, there 
was no significant effect of NT-proBNP–guided therapy on the 
primary end point survival free of hospitalization, although the 
secondary end point survival free of HF hospitalization was 
positively influenced in the overall population.7 Also, patients 
aged 60 to 74 years of age clearly benefitted from intensified 
therapy with regard to both HF  hospitalization-free and over-
all survival, whereas those aged ≥75 years did not show any 
benefit at all.7 Age groups in TIME-CHF were prestratified 
and other trials had similar findings with regard to age,8 but 
still it has to be noted that this was a subgroup analysis. In 
this regard, the long-term results presented here are important 
because the persisting and even slightly augmenting effect 
beyond the intervention period confirms the positive effect 
of NT-proBNP–guided therapy in the younger age group, 
whereas a regression toward the mean would point toward a 
chance finding.
It is important to note that the long-term outcome of our pop-
ulation was poor on hospitalizations and mortality. The 5-year 
mortality rate in TIME-CHF of 39% is comparable with that of 
several large registries, ranging from 31% to 49%,20,21 showing 
that our population is highly representative of the real-life HF 
population. Previous investigations of (NT-pro)BNP-guided 
treatment of patients with HF have mainly reported short- or 
midterm results.1,5,10,12,15,17,22,23 The BATTLESCARRED study 
was to date the only study that reported follow-up results ≤1 
year after the intervention period,8 showing that the positive 
effects of NT-proBNP–guided therapy are maintained after 
cessation of the guided strategy. We extend these results to 
4 instead of 1 year of additional follow-up after the interven-
tion period, showing that the initial beneficial effect remains 
present long term after cessation of the NT-proBNP–guided 
strategy.  TIME-CHF applied treatment strategies for a shorter 
period compared with BATTLESCARRED, indicating that it 
might be sufficient to apply the NT-proBNP–guided strategy 
Figure 2. Interactions between patient characteristics and treatment allocation on long-term outcome. Bars indicate 95% confidence 
interval (CI) of the hazard ratio, error bars indicate 99% CI of the hazard ratio. Interactions: aP<0.05; bP<0.10. BMI indicates body mass 
index; comorb, comorbidities; HF, heart failure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal Pro-B-type natriuretic 
 peptide; and NYHA, New York Heart Association.
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for a shorter period to reach similar results. The protocol 
of  TIME-CHF aimed to uptitrate medication as far as pos-
sible within 6 months, but NT-proBNP measurements were 
repeated after 12 and 18 months, allowing further adjustment 
of therapy if required. Based on our current knowledge and 
based on the protocol of the study, we would advise clinicians 
to implement a NT-proBNP–guided strategy for individual-
ized uptitration for a limited duration of 6 to 12 months only 
with 1 or 2 control measurements thereafter. However, it is 
important to note that our results are insufficient to make 
definite conclusions about the best time frame. Therefore, 
further research is needed to assess whether a short period 
of individualized, biomarker-guided intensification of HF 
medication could improve outcome. The currently ongo-
ing GUIDE-IT (Guiding Evidence Based Therapy Using 
Biomarker Intensified Treatment) trial,24 planned to be the 
largest NT-proBNP–guided trial thus far, will hopefully be 
able to give more definite answers.
Despite general consensus on medical therapy in HF with 
reduced left ventricular ejection fraction,16 there is a rela-
tive underuse and insufficient uptitration of HF medication in 
current clinical practice,25,26 particularly in the elderly.27–30 A 
performance improvement intervention, including education, 
decision support, and other support tools, could improve doses 
of β-blockers but not that of RAS blockade or MRAs in an 
outpatient setting.26 Interestingly, patients with known BNP 
levels did not differ in the use of  guideline-recommended HF 
therapies compared with those with unknown BNP levels, 
but patients with the highest BNP levels were less likely to be 
treated with RAS blockers or MRAs, whereas they are probably 
at highest risk of adverse outcome.31 Thus, there is undoubt-
edly room for further improvement of treatment. (NT-pro)BNP-
guided therapy led to more intensification of HF medication 
in most5,8,10,12,15,17 but not all22,23 guided trials. In TIME-CHF, 
patients who actually had more intensified HF medical ther-
apy at 12 months had significantly better outcome compared 
with those with less intensified medical therapy. These results 
need to be taken cautiously because there might be bias, as the 
sickest patients are those in whom it is most difficult to inten-
sify HF medication and landmark analysis does not take into 
account confounding. Still, the positive and long-term effects of 
NT-proBNP–guided therapy seem at least in part attributable to 
the achievement of more intensified HF therapy.
The lack of effect of NT-proBNP–guided, intensi-
fied treatment in the more elderly is a matter of discus-
sion. NT-proBNP was shown previously to have important 
Figure 3. Kaplan–Meier curve landmark analysis by relative doses of heart failure (HF) medication. A, Considering renin–angiotensin 
system (RAS) blockers and β-blockers. Solid thick line, RAS blockade and β-blocker ≥50% target dose; dashed line, RAS blockade or 
β-blocker ≥50% target dose; solid thin line, RAS blockade and β-blocker <50% target dose. B, Considering RAS blockers, β-blockers, 
and mineralocorticoid antagonists (MRAs). Score consists of RAS blockade ≥50% target dose=1 point; β-blocker ≥50% target dose=1 
point; MRA use=1 point. Solid black thick line, 3 points; dashed thick line, 2 points; solid black thin line, 1 points; dashed thin line, 0 
points. The zero time point on the x-axis represents the 12-month landmark point.
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prognostic capacity also in the elderly patients, despite a gen-
eral increased concentration in older patients.32 Therefore, 
we used  age-dependent target concentrations in TIME-CHF, 
making it unlikely that NT-proBNP characteristics are causing 
the difference in age groups. Although current HF guidelines 
advise to apply therapy regardless of age and comorbidities,16 
the recommendations are mainly based on subgroup analy-
ses33,34 because large HF medication trials have included rela-
tively young patients with little comorbidities and specific 
trials in the elderly are scarce.35 In our study, NT-proBNP 
guidance led to more intensified HF medication, both in the 
younger and older age groups. Even more so, MRAs were 
intensified by NT-proBNP–guided therapy primarily in those 
aged ≥75 years. Despite, NT-proBNP–guided therapy failed 
to be effective in those aged ≥75 years and the positive effect 
of actual intensified therapy at month 12 was also lacking in 
the more elderly. This underlines the suggestion that stringent 
intensification of HF medication might not be most optimal 
in the elderly and the question should be raised whether a 
 one-size fits all add-on therapy is really the best way to go in 
all patients with HF.
Limitations
Long-term follow-up was defined per protocol,18 but separate 
informed consent had to be obtained. Consequently, not all 
patients agreed on further being contacted after completion 
of the first 18 months. Still, a large number of patients agreed 
to long-term follow-up. Long-term follow-up was conducted 
only by telephone and chart review and did not include symp-
toms or medication. Thus, there is no information on eventual 
changes in medication beyond 18 months. In addition, land-
mark analysis ignores changes in group membership after the 
landmark time. As such, patients who reached more intensi-
fied levels of HF medication beyond month 12 are still clas-
sified as nonresponders. Furthermore, landmark analysis is 
an observational data analysis because group membership is 
determined at the landmark time point according to response 
to treatment. However, confounding in landmark analysis for 
the randomized treatment arms was limited. Also, the land-
mark point was selected a priori as the uptitration period of 
12 months,18 preventing data-driven results. Moreover, by 
presenting both the landmark analysis next to the overall sur-
vival time results, we have incorporated the landmark analy-
sis as a form of sensitivity analysis as recommended.36 With 
regard to the analysis on the effect of actual intensification 
of medication, it needs to be stated that the Kaplan–Meier 
curves divided by medication doses at month 12 intersect, 
making it difficult to interpret these results and draw defi-
nite conclusions. Blinding of physicians was not able in this 
study design. However, an end point committee blinded to 
group allocation evaluated all study end points. Although the 
uptitration scheme was predefined per protocol, physicians 
treated patients according to their own discretion. Finally, 
subgroup analyses besides the age groups were not prestrati-
fied and should be considered hypothetical.
Conclusions
Intensified, NT-proBNP–guided therapy did not improve 
the primary end point on the long-term compared with 
symptom- guided therapy, whereas it did improve long-term 
survival free of HF hospitalization versus symptom-guided 
therapy, a secondary but disease-specific end point of the 
study. In the predefined age group of 60 to 74 years, clini-
cal outcome including the primary end point was influenced 
positively, whereas no effects were seen in patients aged ≥75 
years. Importantly, the effects of NT-proBNP–guided therapy 
were maintained after cessation of this strategy during the 
long term. Possibly, this is attributable to a more intensified 
HF medical therapy in the NT-proBNP–guided group as seen 
after completion of uptitration of medication. Further research 
is needed to assess whether a short period of individualized, 
biomarker-guided intensification of HF medication could 
improve outcome and whether particular groups of patients 
profit most from this approach.
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CLINICAL PERSPECTIVE
The role of N-terminal-pro-B-type natriuretic peptide to guide and intensify heart failure (HF) management continues to be 
debated. Although trial results to date are not uniform, taken altogether they suggest that N-terminal-pro-B-type natriuretic 
peptide–guided therapy results in intensification of medical HF therapy and may improve outcome. It remains unknown what 
the long-term effects are of this strategy and whether the benefits persist after the guided-strategy phase ends. This analysis 
of the randomized controlled Trial of Intensified versus Standard Medical therapy in Elderly Patients with Congestive Heart 
Failure includes 5-year follow-up and shows that N-terminal-pro-B-type natriuretic peptide–guided therapy is not effective 
in improving the primary trial end point. There was an apparent favorable effect on long-term HF hospitalization-free sur-
vival in patients with HF with reduced left ventricular ejection fraction, age ≥60 years, possibly attributable to more intensi-
fied medical HF therapy. The initial positive effect of N-terminal-pro-B-type natriuretic peptide–guided therapy, which was 
only observed in the patients aged 60 to 74 years—prestratified per protocol—did not regress to the mean in a landmark 
analysis starting at 12 months. Similar to the main study results, there was no effect of the intervention in patients ≥75 years. 
Overall prognosis remains poor (mortality rate 40%), despite near-optimal medical HF therapy. Because we included a rep-
resentative elderly and highly comorbid HF population in our trial, the results presented should be generalizable.
